Has John Keggi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $263,666 in general payments to John Keggi, MD across 239 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Keggi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Keggi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Keggi, MD

Orthopaedic Surgery · Middlebury, CTNPI 1952366072

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Omnilife Science, Inc at 60.0% of the total. Reporting peaked in 2019 at $168,509 and has fallen 98.4% since, to $2,708 in 2025. Among orthopaedic surgery clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$263,666in general payments, 2019–2025

Across 239 payments — averaging $1103.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Omnilife Science, Inc$158K
Smith+Nephew$56K
Corin USA$25K
Medtronic$21K
Arthrex$1K
Medacta USA, Inc.$1K
plus $591 from 3 others

$30,070in research payments, 2019–2025

Across 17 payments — averaging $1768.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Omnilife Science, Inc$28K
Corin USA$2K

$104,988in ownership & investment interests, 2019–2025

Across 3 payments — averaging $34,996 each. An ownership or investment interest held by the physician or an immediate family member.

Omnilife Science, Inc$105K

What the payments were for

Royalty or licence$7,9753%
Consulting fees$128,60649%
Speaking & faculty fees$64,30324%
Travel & lodging$37,41114%
Food & beverage$25,37210%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Omnilife Science, Inc	160	$158,178
Smith+Nephew	35	$56,339
Corin USA	16	$25,008
Medtronic	11	$21,320
Arthrex	7	$1,228
Medacta USA, Inc.	3	$1,002
Naviswiss, Inc.	4	$370
Zimmer Biomet	2	$144
Stryker	1	$77

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$263,666 in reported general payments places this provider in the 95th percentile of 273 orthopaedic surgery providers in Connecticut.

See all orthopaedic surgery providers in Connecticut →

Medicare billing

Part B allowed, 2024

$303,609

Medicare patients

579

Services billed

4,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Meloxicam	261	$546
Celecoxib	24	$210
Vitamin D2Ergocalciferol (Vitamin D2)	17	$98

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Middlebury

Robert KennonMiddlebury$37K
Peter WhangNew Haven$1.8M
Paul SethiGreenwich$1.5M
James YueShelton$1.3M
Robert DeveneyDanbury$907K
James PaceFarmington$721K
Isaac MossFarmington$676K
David FrumbergNew Haven$288K
Lauren GeaneyFarmington$263K
Robert StantonFairfield$199K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →